Back to Search Start Over

Targeted PEG-poly(glutamic acid) complexes for inhalation protein delivery to the lung.

Authors :
Nieto-Orellana A
Li H
Rosiere R
Wauthoz N
Williams H
Monteiro CJ
Bosquillon C
Childerhouse N
Keegan G
Coghlan D
Mantovani G
Stolnik S
Source :
Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2019 Dec 28; Vol. 316, pp. 250-262. Date of Electronic Publication: 2019 Oct 31.
Publication Year :
2019

Abstract

Pulmonary delivery is increasingly seen as an attractive, non-invasive route for the delivery of forthcoming protein therapeutics. In this context, here we describe protein complexes with a new 'complexing excipient' - vitamin B <subscript>12</subscript> -targeted poly(ethylene glycol)-block-poly(glutamic acid) copolymers. These form complexes in sub-200nm size with a model protein, suitable for cellular targeting and intracellular delivery. Initially we confirmed expression of vitamin B <subscript>12</subscript> -internalization receptor (CD320) by Calu-3 cells of the in vitro lung epithelial model used, and demonstrated enhanced B <subscript>12</subscript> receptor-mediated cellular internalization of B <subscript>12</subscript> -targeted complexes, relative to non-targeted counterparts or protein alone. To develop an inhalation formulation, the protein complexes were spray dried adopting a standard protocol into powders with aerodynamic diameter within the suitable range for lower airway deposition. The cellular internalization of targeted complexes from dry powders applied directly to Calu-3 model was found to be 2-3 fold higher compared to non-targeted complexes. The copolymer complexes show no complement activation, and in vivo lung tolerance studies demonstrated that repeated administration of formulated dry powders over a 3 week period in healthy BALB/c mice induced no significant toxicity or indications of lung inflammation, as assessed by cell population count and quantification of IL-1β, IL-6, and TNF-α pro-inflammatory markers. Importantly, the in vivo data appear to suggest that B <subscript>12</subscript> -targeted polymer complexes administered as dry powder enhance lung retention of their protein payload, relative to protein alone and non-targeted counterparts. Taken together, our data illustrate the potential developability of novel B <subscript>12</subscript> -targeted poly(ethylene glycol)-poly(glutamic acid) copolymers as excipients suitable to be formulated into a dry powder product for the inhalation delivery of proteins, with no significant lung toxicity, and with enhanced protein retention at their in vivo target tissue.<br /> (Copyright © 2019 Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1873-4995
Volume :
316
Database :
MEDLINE
Journal :
Journal of controlled release : official journal of the Controlled Release Society
Publication Type :
Academic Journal
Accession number :
31678655
Full Text :
https://doi.org/10.1016/j.jconrel.2019.10.012